{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:24:46Z","timestamp":1794245086618,"version":"4.9.0"},"reference-count":45,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2017,7,3]]},"DOI":"10.1080\/13696998.2017.1325744","type":"journal-article","created":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T16:28:14Z","timestamp":1494433694000},"page":"740-748","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study"],"prefix":"10.1080","volume":"20","author":[{"given":"James","family":"Kenworthy","sequence":"first","affiliation":[{"name":"Mundipharma International Limited, Cambridge, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunni","family":"Yi","sequence":"additional","affiliation":[{"name":"PHMR, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Wright","sequence":"additional","affiliation":[{"name":"PHMR, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Brown","sequence":"additional","affiliation":[{"name":"PHMR, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Maria Madrigal","sequence":"additional","affiliation":[{"name":"PHMR, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C. N.","family":"Dunlop","sequence":"additional","affiliation":[{"name":"Mundipharma International Limited, Cambridge, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"key":"CIT0001","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. United Kingdom country overview. 2016. http:\/\/www.emcdda.europa.eu\/countries\/united-kingdom#prevalence. Last accessed March 17, 2017"},{"key":"CIT0002","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. European drug report 2016: trends and developments. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2016"},{"key":"CIT0003","volume-title":"Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence","author":"World Health Organization","year":"2009"},{"key":"CIT0004","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. The state of the drugs problem in Europe. Annual report 2011. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2011"},{"key":"CIT0005","first-page":"CD011117","author":"Nielsen S","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2016.1100960"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw416"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1258\/135581905774414187"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-017-0071-3"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.3310\/hta11090"},{"key":"CIT0011","unstructured":"Tosh J, Wailoo A. Review of software for decision modelling. 2008. http:\/\/www.nicedsu.org.uk\/PDFs of reports\/softwarereport-final.pdf. Accessed 3rd March 2017"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-010-0043-7"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1111\/add.12906"},{"key":"CIT0014","volume-title":"Home Office Research Study 249: The economic and social costs of Class A drug use in England and Wales, 2000","author":"Godfrey C","year":"2002"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00296.x"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.173.2.166"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2016.1195608"},{"key":"CIT0018","first-page":"CD011117","author":"Nielsen S","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826090-00004"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.12.031"},{"key":"CIT0021","volume-title":"National guidelines for medication-assisted treatment of opioid dependence","author":"Gowing L","year":"2014"},{"key":"CIT0022","first-page":"CD009879","author":"Ferri M","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1111\/add.12440"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000288"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1159\/000368572"},{"key":"CIT0026","unstructured":"National Health Service Business Services Authority. NHS Prescription Services. 2016. http:\/\/www.nhsbsa.nhs.uk\/PrescriptionServices.aspx. Accessed 7th March 2017"},{"key":"CIT0027","volume-title":"British National Formulary (BNF) 67. June","author":"British Medical Association, Royal Pharmaceutical Society","year":"2016"},{"key":"CIT0028","unstructured":"Pharmaceutical Services Negotiating Committee. Fees and allowances 2016. http:\/\/psnc.org.uk\/dispensing-supply\/endorsement\/fees-allowances\/. Accessed 16th March 2017"},{"key":"CIT0029","unstructured":"Thurrock Council. Supervised Consumption Primary Care Contact. 2016; https:\/\/www.thurrock.gov.uk\/information-for-gps-and-pharmacies\/supervised-consumption-primary-care-contracts. Accessed 3rd March 2017"},{"key":"CIT0030","volume-title":"Unit costs of health and social care 2016","author":"Curtis L.","year":"2016"},{"key":"CIT0031","unstructured":"Department of Health. National schedule of reference costs (2015\u20132016). https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2015-to-2016. Accessed 7th March 2017"},{"key":"CIT0032","unstructured":"Office for National Statistics. Consumer price inflation, September 2016. https:\/\/www.ons.gov.uk\/economy\/inflationandpriceindices\/bulletins\/consumerpriceinflation\/sept2016. Accessed 7th March 2017"},{"key":"CIT0033","volume-title":"Data tables of the unlinked anonymous monitoring survey of HIV and hepatitis in people who inject drugs. Surveillance update: July 2016","author":"Public Health England","year":"2016"},{"key":"CIT0034","unstructured":"Home Office. Drug misuse: findings from the 2015 to 2016 CSEW: data tables. 2016. https:\/\/www.gov.uk\/government\/statistics\/drug-misuse-findings-from-the-2015-to-2016-csew. Accessed 3rd March 2017"},{"key":"CIT0035","unstructured":"Office for National Statistics. Annual mid-year population estimates: mid 2015. Accessed 16th March 2017"},{"key":"CIT0036","unstructured":"Public Health England. HIV diagnoses, late diagnoses and numbers accessing treatment and care: 2016 report. London: Public Health England; 2016"},{"key":"CIT0037","unstructured":"Public Health England. Hepatitis C in the UK 2016 report. London: Public Health England; 2016"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015677"},{"key":"CIT0039","volume-title":"Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV\/HIV co-infection: a systematic review and economic evaluation","author":"National Institute of Health and Care Excellence","year":"2009"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.06.036"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1186\/s41124-016-0002-z"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.90.7.1100"},{"key":"CIT0044","volume-title":"NICE DSU technical support document 12: the use of health state utility values in decision models","author":"Ara R","year":"2011"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000197027.06808.e2"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2017.1325744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T19:48:51Z","timestamp":1599421731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2017.1325744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7,3]]}},"alternative-id":["10.1080\/13696998.2017.1325744"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2017.1325744","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-12-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}